ResMed said revenue for the 3 months ended March 31, 2024 was $1,197.0 million, up 7% from $1,116.9 million a year earlier, and rose 7% on a constant currency basis.

1. 01

   ResMed said revenue for the 3 months ended March 31, 2024 was $1,197.0 million, up 7% from $1,116.9 million a year earlier, and rose 7% on a constant currency basis.

2. 02

   The company said gross margin for the 3 months rose from 55.3% to 57.9%, and income from operations increased 25% to $374.6 million. It cited lower freight costs and manufacturing cost improvements as factors behind the gross margin increase.

3. 03

   The company said operating cash flow for the 3 months was $402 million, and it paid $220 million to repay borrowings over the same period. Net income was $300.5 million.

4. 04

   The company said its board declared a quarterly cash dividend of US $0.48 per share, with a record date of May 9, 2024 and a payment date of June 13, 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.